-
公开(公告)号：EP3971206A1
公开(公告)日：2022-03-23
申请号：EP21178401.2
申请日：2012-02-07
申请人： Roche Glycart AG
发明人： AST, Oliver , BRUENKER, Peter , FREIMOSER-GRUNDSCHOBER, Anne , HERTER, Sylvia , HOFER, Thomas U. , HOSSE, Ralf , KLEIN, Christian , MOESSNER, Ekkehard , NICOLINI, Valeria G. , UMAÑA, Pablo
摘要： The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the α-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
-
公开(公告)号：EP2691417B1
公开(公告)日：2018-08-01
申请号：EP12710732.4
申请日：2012-03-27
申请人： Roche Glycart AG
发明人： BAEHNER, Monika , JENEWEIN, Stefan , KUBBIES, Manfred , MOESSNER, Ekkehard , SCHLOTHAUER, Tilman
CPC分类号： C07K16/2896 , C07K16/00 , C07K2317/52 , C07K2317/56 , C07K2317/71 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/92 , C07K2319/30 , Y10S435/81
摘要： The invention relates to engineered polypeptides comprising Fc variants and their uses. More specifically, Fc variants are described exhibiting reduced effector function. These variants cause a benefit for a patient suffering from a disease which could be treated with an antibody for which it is desirable to reduce the effector function elicited by antibodies.
-
公开(公告)号：EP2882458B1
公开(公告)日：2018-07-11
申请号：EP13745844.4
申请日：2013-08-07
申请人： Roche Glycart AG
发明人： HOSSE, Ralf , KLEIN, Christian , MOESSNER, Ekkehard , PETERSON, Laurence Bernard , UMANA, Pablo , WICKER, Linda
CPC分类号： C07K14/55 , A61K38/2013 , C07K16/18 , C07K16/46 , C07K2317/21 , C07K2319/00 , C07K2319/30
摘要： The present invention generally relates to fusion proteins of immunoglobulins and interleukin-2 (IL-2). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.
-
公开(公告)号：EP3333194A1
公开(公告)日：2018-06-13
申请号：EP17198743.1
申请日：2011-08-09
申请人： Roche Glycart AG
发明人： BACAC, Marina , FREIMOSER-GRUNDSCHOBER, Anne , HOSSE, Ralf , KLEIN, Christian , MOESSNER, Ekkehard , NICOLINI, Valeria G. , UMANA, Pablo
IPC分类号： C07K16/40
CPC分类号： C07K16/40 , A61K47/6871 , A61K51/1075 , C07K16/30 , C07K2317/21 , C07K2317/33 , C07K2317/41 , C07K2317/55 , C07K2317/565 , C07K2317/732 , C07K2317/92
摘要： The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same.
-
公开(公告)号：EP3333193A1
公开(公告)日：2018-06-13
申请号：EP17203491.0
申请日：2012-02-29
申请人： Roche Glycart AG
IPC分类号： C07K16/30
CPC分类号： C07K16/42 , A61K39/39566 , A61K45/06 , A61K2039/505 , A61N5/10 , C07K16/3007 , C07K2317/24 , C07K2317/41 , C07K2317/565 , C07K2317/732 , C07K2317/92 , C07K2317/94
摘要： The present invention provides antigen binding molecules (ABMs) which bind membrane-bound CEA, including ABMs with improved therapeutic properties, and methods of using the same.
-
6.发明公开BISPECIFIC ANTIBODIES SPECIFIC FOR FAP AND DR5, ANTIBODIES SPECIFIC FOR DR5 AND METHODS OF USE 审中-公开特异性FAP和DR5，特异性抗体DR5和使用方法特异性抗体
公开(公告)号：EP2981552A1
公开(公告)日：2016-02-10
申请号：EP14714275.6
申请日：2014-04-01
申请人： Roche Glycart AG
发明人： BRUENKER, Peter , DAOUTI, Sherif , FENG, Ningping , FERRARA KOLLER, Claudia , GEORGES, Guy , GRAU-RICHARDS, Sandra , HOSSE, Ralf , KLEIN, Christian , KOENIG, Maximiliane , MOELLEKEN, Joerg , MOESSNER, Ekkehard , NIU, Huifeng , PACKMAN, Kathryn E. , RUNZA, Valeria , SEEBER, Stefan , UMANA, Pablo , WALDHAUER, Inja , WANG, Huisheng , WEISER, Barbara
CPC分类号： C07K16/40 , A61K2039/505 , C07K16/2875 , C07K16/2878 , C07K16/30 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/35 , C07K2317/52 , C07K2317/55 , C07K2317/624 , C07K2317/64 , C07K2317/66 , C07K2317/73 , C07K2317/75 , C07K2317/92 , C07K2317/94 , C07K2319/00
摘要： The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
摘要翻译： 本发明涉及包含特异性针对DR5的至少一个抗原结合位点和特异性针对FAP的至少一个抗原结合位点的双特异性抗体，特异于DR5它们的生产方法的抗体，药物组合物含有所述抗体，及其用途。
-
公开(公告)号：EP2961772A1
公开(公告)日：2016-01-06
申请号：EP14707126.0
申请日：2014-02-24
申请人： Roche Glycart AG
发明人： HOFER, Thomas , HOSSE, Ralf , MOESSNER, Ekkehard
IPC分类号： C07K16/30 , A61K39/395 , A61P35/00
CPC分类号： C07K16/30 , A61K2039/505 , C07K16/3053 , C07K2317/24 , C07K2317/30 , C07K2317/33 , C07K2317/41 , C07K2317/56 , C07K2317/565 , C07K2317/72 , C07K2317/732 , C07K2317/92
摘要： The invention provides anti-MCSP antibodies and methods of using the same.
-
公开(公告)号：EP2882458A1
公开(公告)日：2015-06-17
申请号：EP13745844.4
申请日：2013-08-07
申请人： Roche Glycart AG
发明人： HOSSE, Ralf , KLEIN, Christian , MOESSNER, Ekkehard , PETERSON, Laurence Bernard , UMANA, Pablo , WICKER, Linda
CPC分类号： C07K14/55 , A61K38/2013 , C07K16/18 , C07K16/46 , C07K2317/21 , C07K2319/00 , C07K2319/30
摘要： The present invention generally relates to fusion proteins of immunoglobulins and interleukin-2 (IL-2). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.
摘要翻译： 本发明一般涉及免疫球蛋白和白细胞介素-2（IL-2）的融合蛋白。 此外，本发明涉及编码这种融合蛋白的多核苷酸，以及包含这种多核苷酸的载体和宿主细胞。 本发明进一步涉及本发明的融合蛋白的制备方法及其在疾病治疗中的应用。
-
公开(公告)号：EP2483310B1
公开(公告)日：2014-08-13
申请号：EP10757604.3
申请日：2010-09-27
申请人： Roche Glycart AG
发明人： BRUENKER, Peter , FERRARA KOLLER, Claudia , GRAU, Sandra , HERTER, Sylvia , LAMPERT, Christoph , MOESSNER, Ekkehard , UMANA, Pablo , WALDHAUER, Inja
CPC分类号： C07K16/2878 , C07K16/18 , C07K16/30 , C07K16/3007 , C07K16/40 , C07K2317/31 , C07K2317/73
-
公开(公告)号：EP2691417A1
公开(公告)日：2014-02-05
申请号：EP12710732.4
申请日：2012-03-27
申请人： Roche Glycart AG
发明人： BAEHNER, Monika , JENEWEIN, Stefan , KUBBIES, Manfred , MOESSNER, Ekkehard , SCHLOTHAUER, Tilman
IPC分类号： C07K16/28
CPC分类号： C07K16/2896 , C07K16/00 , C07K2317/52 , C07K2317/56 , C07K2317/71 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/92 , C07K2319/30 , Y10S435/81
摘要： The invention relates to engineered polypeptides comprising Fc variants and their uses. More specifically, Fc variants are described exhibiting reduced effector function. These variants cause a benefit for a patient suffering from a disease which could be treated with an antibody for which it is desirable to reduce the effector function elicited by antibodies.
-
-
-
-
-
-
-
-
-
搜索结果
56 条记录 (耗时 0.046 秒)
